FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...
MPR

Subcutaneous Lecanemab Starting Dose Under Review for Alzheimer Disease

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
The Portugal News

Paying for diabetes medication

The Azores Health Service will reimburse 100% of the cost of medical devices for the treatment of type 1 diabetes mellitus ...

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s …

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
Le Lézard

Leqembi® Iqliktm (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) ...

Eisai Inc.: FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...
Oncology Nurse Advisor

FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Pharmabiz

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology: Daejeon, South Korea Wednesday, January 21, 2026, ...
Everyday Health on MSN

How to plan for successful home SCIg self-administration for primary immunodeficiency

Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...